Johnson & Johnson has entered into a definitive agreement to acquire Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialisation of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value of approximately $14.6 billion.

Through the acquisition, Johnson & Johnson will enhance its neuroscience portfolio with CAPLYTA (lumateperone), an FDA-approved treatment for schizophrenia and bipolar depression, and will leverage Intra-Cellular’s pipeline, including a Phase 2 compound for generalised anxiety disorder and Alzheimer’s-related psychosis and agitation. The acquisition aims to strengthen Johnson & Johnson’s position in treating neuropsychiatric and neurodegenerative disorders.